Use of Rh immune globulin: ASCP practice parameter. American Society of Clinical Pathologists.
The use of Rh immune globulin (RhIG) has dramatically decreased the incidence of hemolytic disease of the fetus and newborn resulting from the production of anti-D by an Rh-negative woman. However, despite the widespread use of RhIG, instances of Rh immunization continue to occur, most likely through failure to administer RhIG when indicated or in the appropriate dose. This utilization gap can be closed only through continued active surveillance by health care providers. The following report summarizes recommendations for the administration of RhIG, the dose required in various circumstances, prenatal and postnatal serologic testing of the obstetric patient, and the methods used to determine the degree of fetomaternal hemorrhage or the amount of Rh-positive RBCs in the circulation.
Hartwell
E A
EA
Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, USA.
D004899:Erythroblastosis, Fetal / Q000175:diagnosis / Q000517:prevention & control*; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D005331:Fetomaternal Transfusion / Q000175:diagnosis; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage*; D012698:Serologic Tests
D018029:Rho(D) Immune Globulin